Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)

LIFECORE BIOMEDICAL, INC. DE

2024-Q3 EPS reported $0.52 revenue$90,375,000

Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.
Full-year FY2024 guidance: revenue $125M-$130M, adjusted EBITDA $13.5M-$16.9M.
Development portfolio grows to 33 projects (+4 YoY); prospective pipeline has 68 opportunities.
Capacity expansion: theoretical capacity to triple to ~70M units by FY2027; 5-head filler GMP-ready Aug 2024.
Alcon HA supply agreement: capacity up 38% in FY2024; further 20% yield improvement expected in FY2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.